CN118488837A - 用于治疗胃癌的化合物 - Google Patents

用于治疗胃癌的化合物 Download PDF

Info

Publication number
CN118488837A
CN118488837A CN202280082007.5A CN202280082007A CN118488837A CN 118488837 A CN118488837 A CN 118488837A CN 202280082007 A CN202280082007 A CN 202280082007A CN 118488837 A CN118488837 A CN 118488837A
Authority
CN
China
Prior art keywords
formula
pharmaceutically acceptable
alkyl
halo
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280082007.5A
Other languages
English (en)
Chinese (zh)
Inventor
V·K·维什纽达斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bu Pu Ge Biopharmaceutical Co
Original Assignee
Bu Pu Ge Biopharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bu Pu Ge Biopharmaceutical Co filed Critical Bu Pu Ge Biopharmaceutical Co
Publication of CN118488837A publication Critical patent/CN118488837A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280082007.5A 2021-11-17 2022-11-17 用于治疗胃癌的化合物 Pending CN118488837A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163280540P 2021-11-17 2021-11-17
US63/280,540 2021-11-17
PCT/US2022/050289 WO2023091590A1 (en) 2021-11-17 2022-11-17 Compounds for use in treating gastric cancer

Publications (1)

Publication Number Publication Date
CN118488837A true CN118488837A (zh) 2024-08-13

Family

ID=84887956

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280082007.5A Pending CN118488837A (zh) 2021-11-17 2022-11-17 用于治疗胃癌的化合物

Country Status (8)

Country Link
US (1) US20250017906A1 (enExample)
EP (1) EP4433051A1 (enExample)
JP (1) JP2024543111A (enExample)
KR (1) KR20240149878A (enExample)
CN (1) CN118488837A (enExample)
AU (1) AU2022390803A1 (enExample)
CA (1) CA3238430A1 (enExample)
WO (1) WO2023091590A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020417293A1 (en) * 2020-01-03 2022-09-01 Berg Llc Polycyclic amides as UBE2K modulators for treating cancer
WO2024216283A1 (en) * 2023-04-13 2024-10-17 Bpgbio, Inc. Microtubule targeting agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10308617B2 (en) * 2016-06-03 2019-06-04 An2H Discovery Limited Triazole benzamide derivatives and the compositions and methods of treatment regarding the same
CA3112191A1 (en) * 2018-09-10 2020-03-19 Berg Llc Methods of treating cancer by inhibiting ubiquitin conjugating enzyme e2 k (ube2k)
AU2020417293A1 (en) 2020-01-03 2022-09-01 Berg Llc Polycyclic amides as UBE2K modulators for treating cancer

Also Published As

Publication number Publication date
EP4433051A1 (en) 2024-09-25
US20250017906A1 (en) 2025-01-16
JP2024543111A (ja) 2024-11-19
WO2023091590A1 (en) 2023-05-25
CA3238430A1 (en) 2023-05-25
KR20240149878A (ko) 2024-10-15
AU2022390803A1 (en) 2024-06-20

Similar Documents

Publication Publication Date Title
JP5907396B2 (ja) 腫瘍融解症候群の治療薬及び予防薬
US12582653B2 (en) Method for treating idiopathic pulmonary fibrosis
TWI768087B (zh) 包含帕博西尼(palbociclib)及6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯啶-3-基]氧基苯基]-8,9-二氫-7h-苯并[7]輪烯-2-甲酸的組合
US20250017906A1 (en) Compounds for use in treating gastric cancer
CN118139625A (zh) Wee1抑制剂和抗cd47抗体的组合
WO2013112878A1 (en) Mcl-1 modulating compositions
US20260027087A1 (en) Dosing regimens comprising a kat6 inhibitor for the treatment of cancer
JPWO1996032101A1 (ja) 癌転移抑制剤
TW202115091A (zh) 喹啉類似物之結晶型及其鹽類、組合物、及彼等之使用方法
CN114075123B (zh) 苄胺类衍生物及其制备方法与用途
JP6359197B2 (ja) がんの組合せ療法
CN115245515A (zh) 一种组合物的医药用途
AU2024229823B2 (en) Compositions and methods for making and using small molecules for the treatment of health conditions
JPS5823688A (ja) グアニジン誘導体、その製法及びこの化合物を含むヒスタミンｈ−２−「きつ」抗性で胃酸の分泌を抑制する医薬組成物
WO2025202900A1 (en) Cdk4 inhibitors for use in the treatment of mantle cell lymphoma
EP4706656A1 (en) Combination therapy of dacomitinib and nintedanib for prevention or treatment of pulmonary fibrosis
US20250091997A1 (en) Compositions and methods for making and using small molecules for tubulin-targeted therapy in the treatment of cancers and related conditions
JP2025529076A (ja) ＡｈＲ媒介疾患の治療に使用するタピナロおよびそのアナログ製剤
JP2026507880A (ja) がんを治療する方法
KR20240159340A (ko) 폐섬유화 예방 또는 치료를 위한 펙시다티닙 및 닌테다닙의 병용 요법
JPH07101860A (ja) 抗悪性腫瘍剤
HK40064686A (en) Method for treating idiopathic pulmonary fibrosis
JP2022532194A (ja) Ｐｉ３ｋ阻害剤の結晶多形及びその製造方法
JP2000086508A (ja) ヒスタミン遊離抑制剤
TW201828939A (zh) 糖尿病性腎病之治療藥或預防藥

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination